Omega Healthcare Investors (OHI) Q3 2025 earnings summary

Executive summary

• Net income for Q3 2025 was $185 million ($0.59 per share), up from $115 million ($0.42 per share) in Q3 2024, with nine-month net income rising to $437.50 million from $301.34 million year-over-year.

• Adjusted FFO for Q3 2025 was $243 million ($0.79 per share), and FAD was $231 million ($0.75 per share), both up year-over-year, driven by strong revenue and EBITDA growth from acquisitions and portfolio management.

• Major investments included $978 million in new investments YTD 2025, with $151 million in Q3, and a $222 million JV with Saber covering 64 facilities.

• Dividend payout ratios improved to 85% for AFFO and 89% for FAD, with a quarterly dividend of $0.67 per share declared for Q3 2025.

• Portfolio occupancy and EBITDA coverage reached multi-year highs, with only 4.3% of rent from operators below 1x coverage.

Financial highlights

• Q3 2025 total revenues were $312 million, up from $276 million in Q3 2024, with rental income rising to $264.54 million.

• Nareit FFO for Q3 2025 was $242 million ($0.78/share), and FAD was $231 million ($0.75/share), both up from Q3 2024.

• Cash and cash equivalents were $775 million as of September 30, 2025, with $2.3 billion in undrawn credit capacity.

• Ended Q3 with $737 million in cash; repaid $600 million in senior notes in October.

• Total assets were $10.60 billion and total equity was $5.24 billion as of September 30, 2025.

Outlook and guidance

• Full-year 2025 AFFO guidance was raised to $3.08–$3.10 per share, reflecting strong investment activity and JV formation.

• Guidance assumes no further major investments or asset sales beyond those completed by October 30, and continued rent payments from key operators.

• Sufficient liquidity is expected to fund operations, dividends, and investments over the next twelve months.

• Management remains cautious due to ongoing industry challenges, including staffing shortages, inflation, and regulatory uncertainty.

• Pipeline for 2025–2026 remains robust, with substantial U.S. and U.K. opportunities.